SMS Lifesciences India Limited has informed regarding USFDA Inspection.

Regulatory & Legal View source PDF Explain this filing

HALEOSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.4%Reaction day

₹1255.00

prior close

₹1280.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+4.6% vs market

Pharmaceuticals peers, median of 146sector-0.2%+4.7% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

-0.7

15m

-0.7

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.4-0.1+4.6-0.2+4.7

Next day

+7.7+4.5+3.2+2.4+5.3

+16.5+6.2+10.3+4.0+12.5

+12.2+7.9+4.2+4.4+7.8

+13.5+9.0+4.4+5.1+8.4

+9.5+9.9-0.3+5.3+4.2

+4.4+10.0-5.6+5.5-1.1

15d

+4.4+13.1-8.7+7.3-3.0

+0.4+15.5-15.1+7.9-7.5

-3.0+16.8-19.9+8.9-12.0

-7.9+11.3-19.2+3.1-10.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SMS Lifesciences India Limited informed the exchanges that the US Food and Drug Administration (USFDA) completed an inspection at its API manufacturing facility located in Kazipally, Telangana (Unit-1) from May 5 to May 9, 2025. The inspection concluded with one observation in Form 483, which the company clarified is purely procedural in nature and does not relate to data integrity or product quality. The company stated there is no impact on its financial position, operations, or other activities due to this observation. The final Establishment Inspection Report (EIR) is awaited after SMS Lifesciences submits its formal response to the USFDA.

Likely market impact

This is a positive/neutral outcome for shareholders — a single procedural observation with no impact on data integrity, product quality, or operations signals strong compliance, which is supportive of the company's US market prospects. No immediate negative effect on the stock is expected.